109 related articles for article (PubMed ID: 19369937)
1. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.
Vormfelde SV; Brockmöller J; Bauer S; Herchenhein P; Kuon J; Meineke I; Roots I; Kirchheiner J
Clin Pharmacol Ther; 2009 Jul; 86(1):54-61. PubMed ID: 19369937
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
3. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Clin Pharmacol Ther; 2002 Nov; 72(5):562-71. PubMed ID: 12426520
[TBL] [Abstract][Full Text] [Related]
7. Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
9. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
10. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.
Sachse-Seeboth C; Pfeil J; Sehrt D; Meineke I; Tzvetkov M; Bruns E; Poser W; Vormfelde SV; Brockmöller J
Clin Pharmacol Ther; 2009 Mar; 85(3):273-6. PubMed ID: 19005461
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.
Jetter A; Kinzig-Schippers M; Skott A; Lazar A; Tomalik-Scharte D; Kirchheiner J; Walchner-Bonjean M; Hering U; Jakob V; Rodamer M; Jabrane W; Kasel D; Brockmöller J; Fuhr U; Sörgel F
Eur J Clin Pharmacol; 2004 May; 60(3):165-71. PubMed ID: 15045499
[TBL] [Abstract][Full Text] [Related]
12. [Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray].
Li J; Wen SY; Wang R; Chen K; Fang Y; Pei F; Wang SQ
Yao Xue Xue Bao; 2005 Aug; 40(8):695-9. PubMed ID: 16268502
[TBL] [Abstract][Full Text] [Related]
13. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.
Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
Drug Metab Dispos; 2004 May; 32(5):484-9. PubMed ID: 15100169
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.
Perini JA; Vianna-Jorge R; Brogliato AR; Suarez-Kurtz G
Clin Pharmacol Ther; 2005 Oct; 78(4):362-9. PubMed ID: 16198655
[TBL] [Abstract][Full Text] [Related]
15. Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism.
Ikeda T; Aoyama S; Tozuka Z; Nozawa K; Hamabe Y; Matsui T; Kainuma M; Hasegawa S; Maeda K; Sugiyama Y
Eur J Pharm Sci; 2013 Jul; 49(4):642-8. PubMed ID: 23727057
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects.
Bae JW; Kim JH; Choi CI; Kim MJ; Kim HJ; Byun SA; Chang YS; Jang CG; Park YS; Lee SY
Arch Pharm Res; 2009 Feb; 32(2):269-73. PubMed ID: 19280158
[TBL] [Abstract][Full Text] [Related]
17. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
18. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.
Guo Y; Zhang Y; Wang Y; Chen X; Si D; Zhong D; Fawcett JP; Zhou H
Drug Metab Dispos; 2005 Jun; 33(6):749-53. PubMed ID: 15764711
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
20. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats.
Nagata M; Hidaka M; Sekiya H; Kawano Y; Yamasaki K; Okumura M; Arimori K
Drug Metab Dispos; 2007 Feb; 35(2):302-5. PubMed ID: 17132763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
